L. Elhussein

Oral Bisphosphonate Use and All‐Cause Mortality in Patients With Moderate–Severe (Grade 3B‐5D) Chronic Kidney Disease: A Population‐Based Cohort Study

C. Cooper, A. Díez-Pérez, C. Tebé, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Characterising complex health needs and the use of preventative therapies in the older population: a population-based cohort analysis of UK primary care and hospital linked data

D. Prieto-Alhambra, D. Robinson, A. Delmestri, 2022, medRxiv.

Effect of Athena SWAN funding incentives on women’s research leadership

T. Greenhalgh, A. Buchan, Glenn Wells, 2020, BMJ.

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol

P. Hoskin, C. Roberts, T. Maughan, 2020, BMC Cancer.

Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.

C. Cooper, Y. Ben-Shlomo, N. Arden, 2021, Health technology assessment.

The Full Blood Count Blood Test for Colorectal Cancer Detection: A Systematic Review, Meta-Analysis, and Critical Appraisal

S. Kirtley, T. Holt, J. Birks, 2020, Cancers.

Safety of Oral Bisphosphonates in Moderate‐to‐Severe Chronic Kidney Disease: A Binational Cohort Analysis

C. Cooper, A. Díez-Pérez, C. Tebé, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol

P. Hoskin, C. Roberts, T. Maughan, 2020, BMC Cancer.

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer

V. Cerundolo, M. Middleton, C. Roberts, 2023, BJUI compass.

Components of the full blood count as risk factors for colorectal cancer detection: a systematic review protocol

P. Watkinson, S. Kirtley, T. Holt, 2019, BMJ Open.

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma

S. Love, J. Moschandreas, R. Turkington, 2019, European journal of cancer.

Characterising complex health needs and the use of preventive therapies in the older population: a population-based cohort analysis of UK primary care and hospital linked data

D. Prieto-Alhambra, A. Delmestri, A. Jödicke, 2023, BMC Geriatrics.